ArticleScientific reports2019
Preparation of iron oxide mesoporous magnetic microparticles as novel multidrug carriers for synergistic anticancer therapy and deep tumor penetration.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 45 citations in OpenAlex.
- Article
- Design of CoMACS omega · 2025Article
- Imparting of Nearly Superparamagnetic Properties to Cryogel Scaffolds With Mesoporous MNPs for Magneto-Sensitive Tissue Engineering Strategies.Biopolymers · 2024Article
- MICaFVi: A Novel Magnetic Immuno-Capture Flow Virometry Nano-Based Diagnostic Tool for Detection of Coronaviruses.Biosensors · 2023Article
- Curcumin-loaded albumin submicron particles with potential as a cancer therapy: an in vitro study.Beilstein journal of nanotechnology · 2023Article
- Synthesis of novel hybrid mesoporous gold iron oxide nanoconstructs for enhanced catalytic reduction and remediation of toxic organic pollutants.RSC advances · 2022Article
- An Overview of Microparticulate Drug Delivery System and its Extensive Therapeutic Applications in Diabetes.Advanced pharmaceutical bulletin · 2022Review
- Development of a cancer cells self‑activating and miR‑125a‑5p expressing poly‑pharmacological nanodrug for cancer treatment.International journal of molecular medicine · 2022Article
- Micro/Nanosystems for Magnetic Targeted Delivery of Bioagents.Pharmaceutics · 2022Review
- Antifungal Potential of Green Synthesized Magnetite Nanoparticles Black Coffee-Magnetite Nanoparticles Against Wilt Infection by Ameliorating Enzymatic Activity and Gene Expression inFrontiers in microbiology · 2022Article
- Article
- Maghemite (γ-FeMaterials (Basel, Switzerland) · 2021Article
- Recent advances in porous nanostructures for cancer theranostics.Nano today · 2021Article
- One-pot green synthesis of iron oxide nanoparticles from Bauhinia tomentosa: Characterization and application towards synthesis of 1, 3 diolein.Scientific reports · 2021Article
- Iron Oxide Mesoporous Magnetic Nanostructures with High Surface Area for Enhanced and Selective Drug Delivery to Metastatic Cancer Cells.Pharmaceutics · 2021Article
- In vivo effect of magnetic microspheres loaded with E2-a in the treatment of alveolar echinococcosis.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The preparation of mesoporous iron oxides with controllable physiochemical properties for effective therapeutic drug delivery remains a formidable challenge. Herein, iron oxide mesoporous magnetic microparticles (IO-MMMs) were prepared by a modified reverse hard-templating approach using, for the first time, acid-prepared mesoporous spheres (APMS) as the hard silica template. The obtained mesostructures exhibited remarkably high surface area and large pore volumes (S
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.